Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study to Evaluate CCS1477 in Advanced Tumours
Back

Study to Evaluate CCS1477 in Advanced Tumours

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Newcastle Belfast Leicester Glasgow Southampton Manchester Edinburgh Sutton Birmingham Cambridge

Medical Conditions

Carcinoma, Non-Small-Cell Lung

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2018 Aug 2025

Publications

"Eickhoff N, Bergman AM, Zwart W. Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer. Endocrinology. 2022 Oct 11;163(11):bqac153. doi: 10.1210/endocr/bqac153."; "36125208"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Capsules, oral

Intervention Arm Group : CCS1477 Monotherapy - Solid tumours;CCS1477 and abiraterone acetate, combination dose finding and expansion - mCRPC;CCS1477 and atezolizumab, combination dose finding and expansion - non-small cell lung cancer;CCS1477 and darolutamide, combination dose finding and expansion - mCRPC;CCS1477 and enzalutamide, combination dose finding and expansion - mCRPC;CCS1477 and olaparib, combination dose finding and expansion - mCRPC and metastatic breast cancer;CCS1477 dose escalation - mCRPC;CCS1477 expansion phase - mCRPC;

Intervention Type : DRUG
Intervention Description : Abiraterone acetate 500mg tablets plus prednisone/prednisolone

Intervention Arm Group : CCS1477 and abiraterone acetate, combination dose finding and expansion - mCRPC;

Intervention Type : DRUG
Intervention Description : Enzalutamide 40mg capsules/tablets

Intervention Arm Group : CCS1477 and enzalutamide, combination dose finding and expansion - mCRPC;

Intervention Type : DRUG
Intervention Description : 300mg tablets

Intervention Arm Group : CCS1477 and darolutamide, combination dose finding and expansion - mCRPC;

Intervention Type : DRUG
Intervention Description : 150mg tablets

Intervention Arm Group : CCS1477 and olaparib, combination dose finding and expansion - mCRPC and metastatic breast cancer;

Intervention Type : DRUG
Intervention Description : 840mg/14ml concentrate for solution for infusion vials

Intervention Arm Group : CCS1477 and atezolizumab, combination dose finding and expansion - non-small cell lung cancer;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Freeman Hospital
    Newcastle
    NE7 7DN
  • Belfast City Hospital
    Belfast
    BT9 7AB
  • Leicester Royal Infirmary
    Leicester
    LE1 5WW
  • The Beatson West of Scotland Cancer Centre
    Glasgow
    G12 0YN
  • University Hospital Southampton
    Southampton
    SO16 6YD
  • The Christie Hospital
    Manchester
    M20 4BX
  • Edinburgh Cancer Centre Western General Hospital
    Edinburgh
    EH4 2XU
  • Royal Marsden Hospital
    Sutton
    SM2 5NG
  • Queen Elizabeth Hospital Cancer Centre
    Birmingham
    B15 2TH
  • Cambridge University Hospital
    Cambridge
    CB2 0QQ


The study is sponsored by CellCentric Ltd.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03568656
Last updated 27 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top